Infusense m
Carbon 20nanoforest 20electrode 20copy

Infusense

Infusense has pioneered a platform biosensor to measure propofol levels in patients undergoing anesthesia and sedation, improving safety and reducing cost.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Memphis, TN, US
  • Currency USD
  • Founded 2009

Company Summary

Target-controlled infusion anesthesia (TCIA) is used worldwide to deliver the anesthetic drug propofol for general anesthesia and sedation using small pumps, but has not yet been approved by the FDA. The company’s patent-pending platform represents an enabling technology that demonstrates a compelling pharmacoeconomic model that will open up the North American market to TCIA while at the same time making propofol anesthesia and sedation safer.

Advisors

  • Default avatar
    Erno Lindner, Ph.D.
    Professor of Chemistry and R. Eugene Smith Professor of Biomedical Engineering at the University of Memphis.
    Unconfirmed